CURRENT MEDICAL RESEARCH AND OPINION®
VOL. 21, NO. 12, 2005, 2073–2080
© 2005 LIBRAPHARM LIMITED

All rights reserved: reproduction in whole or part not permitted

Indexes to Volume 21

Key to abbreviations: (E) Errata; (L) Letters to the Editor; (Suppl 1) Supplement 1; (Suppl 2) Supplement 2; (Suppl 3) Supplement 3; (Suppl 4) Supplement 4; (Suppl 5) Supplement 5; (Suppl 6) Supplement 6

Author Index

Aagren M 1875
Aapro M 885
Abate G 37
Abbink EJ 1469
Abby S 1403
Abdel-Fattah I 527
Abdelmalek A 1015
Abelson MB 683
Abhyankar B 95
Abuissa H 1107
Abu-Shakra S 381
Adelman J 381
Adler E 1683
Aggarwal J 1677
Agrawala P 769
Agrosì M 1235
Ahmad A 1363
Akashima T 795
Akehurst R 101
Alemao E 1389
Alfonso M 1829
Ali O 1099
Alings AMW 571
Allan L 1819
Allen C 571
Almqvist P S13 (Suppl 3)
Al-Saady N 959
Altman R 1453
Al-Zakwani IS 291
Amadori S 403
Amano J 795
Ambegaonkar A 1755
Amonkar MM 1453
Andersen HF 1659
Ang J 141
Anichkov DA 113
Antonaci S 327
Apajasalo M 1005
Archimandritis AJ 603
Arlot M 185
Armstrong EP 261
Asanuma K 795
Ascher S 849
Asmar RG S17 (Suppl 5)
Assmann G S3 (Suppl 6)
Athyros VG 1157
Avgerinos A 603

Baboolal K 1793
Baccara-Dinet M 1927
Baker CL 749
Baker RW 555
Balkrishnan R 323 (E)
Ballard EE 1611
Banai S 571
Barnes PJ S1 (Suppl 4), S5 (Suppl 4)
Barnett AH S1 (Suppl 1)
Barnhart K 127
Barrett-Connor E 135
Bartorelli L 1809
Bassett R 899, 1969
Baylink DJ 391, 1015
Bell DSH 1107, 1191
Ben-Hamadi R 1677
Berger WE 1519
Bergman H 1317
Bermúdez A 645
Bernstein P 425
Besalduch J 645
Betteridge J 665
Bettzuege-Pfaff BI 1735
Beusterien K 1895
Bihari K 433
Birnbaum HG 195, 1693
Bitto A 777
Blackhouse G 2017
Blijlevens NM 1535
Bloch J 1763
BMS AI424-043 Study Group 1683
Bogossian H 907
Böhler S 619
Bolognese JA 715
Bonaiuto A 777
Bonaiuto M 777
Bönner G 935
Bonnick SL 325 (E)
Borenstein D 1485
Botteman M 47
Botteman MF 741
Bottini G 1809
Boulet L-P 1281
Boyle J 1495
Brady WE 1123
Bramlage P 1433
Brand PLP S27 (Suppl 4)
Branford-White C 1711
Brankin E 475
Brashear HR 483, 1547
Brecher M 923
Brennan A 101
Briney WG 1027
Brixner DI 535
Brohet C 571
Brown RE 1505
Brown RL 1485
Bruckert E 1927
Brühlmann P 1727
Bruni F 1949
Brunton S 71
Brzosko M 517
Bucci R 1969
Buchholz P 1875
Bullano MF 291
Bullock R 1, 1317
Buraglio M 121
Burke N 2017
Bushmakin AG 749
Busman T 245
Busman TA 61
Busse WW 1281
Buys Y 489

Cabelli ST 1297
Calabrese C 495
Calvo-Gomez C 37
Cammarata S 1809
Campbell HE 785
Campo S 777
Cappelleri JC 749
Capri S 913
Cardona-Muñoz EG 1307
Carr-Lopez SM 207
Casais P 1085
Castaldo M 777
Castor AR 1693
Catapano A 1123
Ceccarelli D 899
Chang F-Y 1595
Changchien CR 447
Chapman J 1927
Chapman MJ S17 (Suppl 6)
Chavassieux P 185
Chee I-S 1369
Chen C-C 1595
Chen E 1915
Chen Y-T 1069
Cheng JWM 1857
Chesnut CH 391
Chiacchiarini L 1969
Chiao E 1651
Chik G 333
Childers MK 1485
Choe BM 1369
Choti MA 447
Chowdhury S 1985
Christensen TL 1837
Chruscicki DA 643(E)
Ciervo CA 1641
Cinquegrani M 777
Cipolletta L 495
Clegg JP 805, 817
Cobdeen D 1915
Cobden D 741
Cobitz AR 2029
Cohen C 1683
Cohen M 439
Cohen S 27
Cohen SA 999
Cohen SB 1181
Coleman M 339
Colgan R 1241
Colonna L 1659
Conway D 1915
Conway P 1777, 1793, 2051
Coons J 1801
Cordony A 1617
Cortopassi F 907
Corvol P Sv (Suppl 5)
Coshall C 101
Costagliola M 1235
COSTINE Study Group 645
Covert D 489
Cowden DI 877
Cowen PJ 345
Cowx M 1885
Cramer JA 1453
Crank CW 1923
Crawley J 535
Creasy G 1035
Crisci C 899
Crockett RS 369
Crook MA 333, 1201
Cullen Jnr MT 595
Cunha L 1423
Currie CJ 1477, 1777, 1793, 1905
Curtis SP 715
Cutler DL 1171
Cutrer FM 413
Cyrus P 1241

Daheshia M 587
Dalakas E 1337
Daniel DB 1527
Darensbourg C 1035
Darkow T 1583
Das Gupta R 271
Daskalopoulou SS 231, 307, 959
Davey P 1617
Davidian C 467
Davie AM 805, 817
Davies G 1389
Davies MJ 571
Davis RE 1477
Dawber RPR 1227
Day D 1755
D'Ayala Valva M 495
de Armas E 1711
De Bellis C 1969
De Deyn PP 1423
de Graaf J 1469
Dean BB 981
DeLattre M 47
Delgado A 1763
Desjardins O 2007
DETECT Study Group 619
Devas V 1895
Devulder J 1555
Dew T 1891
Di Loreto G 1139
di Tria AM 899
Dieleman JP 839, 1461
Diener H-C 1603, S18 (Suppl 3)
DiFrancesco D 1115
DiMarino Jnr AJ 27
Dionisio P 1139
Disch D 1441
DISCOVERY PENTA Investigators 1307
Dixon S 1793
Dixon T 1355, 1891
Dobrogowski J 1819
Dodick DW 413
Doherty E 333
Donaldson G 535
Donnenfeld E 643 (E)
Dornhorst A 1401 (L)
Dowell JE 1611
Dowsett SA 1441
Dowson AJ S1 (Suppl 3), S8 (Suppl 3), S13 (Suppl 3), 375
Dramaix M 863
Dueland AN 1297
Duh MS 1677
Dunselman H 1461
Dunselman PHJM 1865
Dupont L 863
DuPont RL 941
D'Urzo A 1281
Dylan M 981

Eaddy MT 1651, 1700
Eagle KA 1209
Edginton T 1329
Edwards SJ 785
Eggert D 1569
Einarson TR 467, 489, 1271, 2007
Elatti EA 527
Elisaf MS 231, 457, 1157, 1997
Elkind-Hirsch KE 1035
Elledge EA 207
Ellis JJ 1209
Ellis P 1985
Ellison H 1241
Elsammak M 527
Elsawaf A 527
Emeriau J-P 37
Emkey R 391, 1895
Emmas C 1905
Emmas CE 785
Erdmann E S21 (Suppl 1)
Erickson SR 1209
Erman MK 223
Etemad LR 1977
Etoricoxib CLBP Study Group 2037
Ettinger MP 391
European Consensus Panel 665
European Medical Writers Association's Ghostwriting Task Force 311
European Study Investigators 37

Fallowfield L 1329
Farahati F 2017
Fasanaro AM 1809
Fastenau J 1347
Fastenau JM 1527
Febbraro S 121
Fenaux P 403
Ferdinand KC 1091
Fernández O 1711
Ferrari MD 413
Fessel WJ 1683
Filippatos TD 457, 1997
Findley LJ 1005
Finlay F 1355
Finn WF 657
Finney MS 1923
Fischer UM 1161
Fisher GE 877
Fisher MD 291
Fleischmann RM 1181
Fonseca FAH 1307
Foos V 2063
Foote M 703 (L)
Fowkes G 101
Frank L 849
Frasca M 1949
Freeman J 339
Freitag FG 381
Fricke Jnr JR 151
Fricke JR 141
Fuat A 375
Fuchs W 935
Fuenmajor N 1307
Fuller-Jonap F 1241
Fyrnys B 827

Gabriel S 19
GAL-INT-28 Study Group 1423
Gallacher SJ 1355
Gallagher AP 1355
Gallagher SC 595
Gama J 345
Gambina G 1317
Gano Jnr A 981
Ganotakis ES 1157
Gao X 47
García M 1829
Garnett WR 1363
Gatifloxacin BID/QID Study Group 425
Gayton JL 1291
Gebhardt U 1261
Geboes K 1741
Genant HK 1027
Gendolla A S3 (Suppl 3), S18 (Suppl 3)
Georgoula M 1997
Geraint M 1595
Gershon S 1485
Gertz H-J 1423
Ghazal A 527
Giannelli G 327
Gidwani S 1961
Giesecke T 1569
Giezek H 2037
Gilbert DG 749
Gill J 1201
Gipe D 1035
Giraldi C 1809
Gitton X 151
Gladysz A 1683
Glaesmer H 619
Glass EV 1027
Gluck JC 1075
Gluck O 1015
Gluck PA 1075
Goadsby PJ 413
Goeree R 2017
Goldstein BJ 2029
Gomes PJ 683
Gonzalez-Garcia J 1683
Gordois A 1617
Gotfried M 245
Gough S 565
Grant PJ S5 (Suppl 1)
Grava MB 173
Gray D 101
Greenberg PE 195
Greener M 271
Griessinger N 1147
Griffiths H 959
Grifka J 2037
Grimaldi L 1969
Gross RH 1057
Grossberg GT 1631
Gruffydd-Jones K 375
Guest JF 81, 271, 281, 447, 805, 817
Gunderson JG 1251
Guo C 1961
Gupta S 1961
Gusman J 863
Gutkin S 1389

Hague LK 2007
Hale ME 1485
Halse J 1027
Ham BJ 1369
Hamilton CW 703 (L)
Hamilton E 1329
Hamilton G 959
Hammond G 1423
Hanefeld M S41 (Suppl 1)
Haribhakti R 769
Harkness M 1355
Harley CR 215
Harris ST 391
Harrison DD 1485
Harrison N 95
Harte C 849
Hartstein I 255
Hauch O 215, 1583
Haughney J 323 (E)
Hayes PC 1337
He Y 1317
Hebborn A 1453
Hellenic Rabeprazole Study Group 603
Hemels MEH 631
Henckler A 1677
Hersh EV 1217
Hindmarch I 1495
Hing JP 483
Hochberg MC 545
Holewijn S 1469
Holgate S 1099
Holló G 1943
Holmstrom S 1837, 1875
Home P 989
Ho-Nguyen Q 121
Hoshiai H 363
Howard DR 769
Howard T 185
Hunt TL 595
Hunt WC 1611
Hupli M 2037

Iannone F 327
Ibach B 723
Innocenzi D 1949
Inui N 369
iRAMT Study Group 1181
Ishikawa H 503
Iskedjian M 489, 2007
Italian Study Group on Nilvadipine in Mild to Moderate Hypertension 951
Ito K-i 795
Iyer S 163

Jackman W 1693
Jackson S 1669
Jacobs A 311, 317, 704 (L)
Jansen JP 1535
Janssens L 1547
Jardim C 907
Jayawardene S 151
Jenkins M 1099
Jenkins V 1329
Jensen H 425
Jiwa M 339
Joesbury H 339
Johnsen S 1495
Johnson LK 1165
Johnson M 1819
Joish VN 535
Jones M 923, 1403
Joshi AV 1755
Joshua-Gotlib S 535
Joy MS 657
Jukema JW 1865
Jumper CA 1611
Jung HY 1369

Kagan R 325 (E)
Kahn BS 509
Kaiser PK 705
Kaliner MA 611
Kalso E 1819
Kamleiter M 723
Kampe S 1569
Kapaki E 871
Kaplan EM 941
Karnon J 101
Karpel JP 1281

Kasper S 1139
Kawai H 503
Keating K 1241
Kee BS 1369
Keech CA 135, 1441
Keenan G 1181
Keene MS 1651 1700
Kemper F 1261
Kennedy-Martin T 1477
Kerney DL 1057
Kessler RC 195
Khan M 163
Khayat D 1763
Khwarg S 255
Kiencke P 1569
Kim DH 93
Kim J 1583
Kim J-B 1369
Kimko H 483
Kimmel D 185
King TR 1123
Kiortsis DN 457, 1997
Kittner B 769
Kivitz A 1895
Klimberg I 1241
Kline-Rogers EM 1209
Klinger T 723
Knauf H 37
Knight K 981
Knorr B 971
Ko Y 1801
Koch U 619
Kohkura K 795
Koltun W 1895
Komuro I 795
Kopsa P 517
Korn D 863
Kosinski MR 849
Kosoglou T 1171
Kóthy P 1943
Kouklakis G 603
Kramarz P 839
Krcevski-Skvarc N 1819
Krege JH 1027
Kreiss A 517
Kremer JM 1181
Krieger JA 1611
Kulasegaram R 1717
Kuritzky L 71, 1701

Lachman A 863
Laforest L 1389
Lage MJ 555
Lally ET 1217
LAM-308 Study Group 657
Lambert-Hammill M 1201
Lammert M 19, 2063
Lanarkshire Osteoporosis Service 475
Landwehr S 1569
Lane R 1317
Lapadula G 327
Laudadio C 1485
Laurent S S7 (Suppl 5)
Lazzari MA 1085
Lecuelle H 121
Lee A 101
Lee AJ 1777
Lee C 1369
Lee JD 357
Lee JM 741
Lee M-S 1369
Lee WC 1915
Lees A 1005
Leger D 1785
Lehman A 81
Lehmann R 517
Lehnert H 619
Leira R 1297
Leone P 1577
Leonetti G 37, 951
Leong SA 195
Levine BS 981
Lévy B S1 (Suppl 5)
Lew KH 1583
Lewiecki EM 1015
Liberman JN 413
Liberman P 611
Liberopoulos EN 231, 457, 1997
Liem A-H 1865
Likar R 1147
Lipton RB 413
Litschig S 517
Littlewood T S1 (Suppl 2)
Lloyd A 323 (E)
Loder E 381
Loder EW S8 (Suppl 3)
Loewy D 223
Lok DJA 1865
Lowe SW 195
Lubowski TJ 1755
Ludwig H 403
Lugan I 121
Lumb PJ 333, 1201
Lupi F 1949
Lutsky B 1281

McCloskey E 805
McCollam PL 1977
McCoy F 1927
McCrory D 413
MacDiarmid S 1413
McEwan P 1793, 1885, 1905
Macfarlane GJ 1819
McGovern R 1683
McKenney J 1403
McKenzie RS 1347, 1677
McLaren C 1683
McQuillian C 1355
Magnussen H S39 (Suppl 4)
Mahamed A 467
Mahlknecht U 1041
Maini M 2037
Mallia-Hughes M 703 (L)
Malmstrom K 141
Malone DC 261
Mancinelli M 899, 1969
Marano CW 1741
Marber MS 1201
Mareva M 1693
Margolis MK 849
Maricic M 1015
Marinosci F 327
Mark TL 1347
Marotti M 1307
Marrero E 1711
Marschall K 827
Martelli F 899
Martino S 1441
Martins B 907
März W 619
Masanauskaite D 1895
Masarachia P 185, 324 (E)
Massaad R 571
Mastrangeli R 1969
Mathur R 1935
Mauch RP 1651, 1700
Maxwell S 1171
Meadows R 1495
Mease PJ 1181
Mehlhorn U 1161
Meis JF 1535
Melzer A 1735
Menditto L 291
Mendola D 899, 1969
Meng T 1261
Meric JB 1763
Merikle E 749
Merl MY 1857
Mershon JL 1441
Meschengieser SS 1085
Metz DC 11
Micangeli E 1969
Mick G 1819
Mielke R 723
Mihai A 81, 271
Mikhailidis DP 231, 307, 357, 457, 959, 1157, 1997
Milani M 1949
Miller PD 391, 545
Minari K 1969
Mishell Jnr DR 509
Mitchell C 475
Mogensen CE S23 (Suppl 5)
Molimard M S33 (Suppl 4)
Monahan ME 1281
Moniz C 1891
Monkman D 959
Montouris G 693
Moore PA 1217
Morales R 2037
Morancey J 1069
Moreland LW 1181
Morgan C 1885
Morgan CLI 1777, 1905
Morita T 503
Morreale A 47
Morrissey JR 357
Morrissey M 1477
Moy J 971
Mozaffari E 839
Mullen J 923
Mundorf TK 369
Munro R 475
Munzel U 827
Murphy KR 1519
Murray C 1261

Nagel J 1317
Naka H 369
Nakai H 363
Narine L 2007
Nataraja SH 1555
Nelson M 215
Nemoto T 503
Nguyen HM 1857
Nicholls C 101
Nicklasson L 741, 1915, 2063
Nicodemus Jnr NA 173
Nieto-Cisneros L 1683
Nikolopoulou V 603
Nilganuwong S 2037
Nischik R 517
Nishimoto H 503
Nishtar S 1201
Nocea G 645
Nordstrom BL 761
Notario G 245
Novack GD 369
O'Brien T 1377
O'Brien TP 93, 1131, 1431(E)
Oderda GM 535
O'Dwyer M 403
Ofman JJ 981
Ogata H 503
Ogawa T 369
Ogilvie AD 345
Ogiwara N 795
Oglesby AK 1617
Oh BH 1369
Oh K-S 1369
Ohtsu Y 795
Oka T 795
O'Keefe Jnr JH 1107
Olivieri L 1139
Olson A 1741
Olufade AO 749
Opdenakker G 1741
O'Reilly D 2017
Ortolani S 1819
Ozturk ZE 2037

Paar WD 1433
Pacini F 495
Paik IH 1369
Palmer AJ 19, 1617, 2063
Palmer R 61, 245
Palmisano J 1123
Pandor A 101
Panetta C 1949
Papasouliotis O 121
Paraskevas E 603
Paraskevas GP 871
Partridge MR S11 (Suppl 4)
Pascual M-J 645
Pashos CL 741, 1915
Pasquine TA 683
Patel K 1741
Patel V 357, 959
Paulsson B 923
Payne H 1329
Pearlman S 381
Peché R 863
Peris MD 1251
Perlini S 913
Perrot S 1819
Perry HD 643 (E), 1057
Perucho A 1819
Peters AL 1935
Peters BS 1717
Peters JR 1477, 1905
Petri M 1485
Pezzotti A 899
Picelli G 839
Piech CT 1347
Piotrovsky V 483
Pitkänen A 1005
Pittard J 959
Pittrow D 619
Plevris JN 1337
Poole C 1885
Potvin E 863
Poulsen PB 1837
Poursain B 1785
Powell R 1099
Price D 323 (E)
Price MJ 733
Przydryga J 255
Pujadas JO 37
Purdie DW 2051
Pyne J 2017

Qu Y 1955

Rabelo R 907
Rabinowitz I 1611
Radeva JI 1527
Rajagopalan R 163, 323 (E)
Ramachandran S 261
Ramey DR 715
Rana Z 467
Rapatz G 1317
Ray JA 1617
Recker R 185, 324 (E)
Recker RR 391
Reed SD 1527
Refai W 527
Regan TS 1651
Reginster J-Y 579
Reicin A 141
Reicin AS 715
Reines EH 1659
Reiss TF 971
Rejas J 1251
Remák E 733, 1505
Reyderman L 1171
Reynolds M 215
Richarz U 1555
Richter-Appelt H 1829
Ridout F 1495
Riedel AA 215
Riffer E 61
Rivkin A 1845
Rixe O 1763
Robertson SM 683
Robinson A 1505
Rodan G 185
Rosen RC 1701
Rosenberg M 1413
Rosenberg MT 509
Rosenstock J 2029
Rosenwasser LJ 1377
Ross PD 545
Rovira M 645
Rowe R 1885
Roybal GM 1935
Roze S 19, 2063
Rubin CD 1049
Ruf G 619
Ruiz A 1251, 1307
Ruiz FJ 81, 271, 281, 447
Ruiz M 1251
Ruskin J 1693
Russ J 271
Russo A 495
Rutgeerts P 1741

Saccardo M 1809
Sachdeo R 1065
Saitta A 777
Saitta C 777
Sanchez-Luceros A 1085
Santora A 185, 324 (E)
Sanz M 403
Sanz MA 645
Sanz-Rodríguez C 645
Sardo MA 777
Sarol Jnr JN 173
Sarracent Y 1711
Sasaki K 795
Sasane R 535
Sashegyi A 135
Sathyan G 1961
Sathyan RR 1065
Savarino V 495
Schachter M 959
Schaefer M 47
Scharf MB 223
Schastnaya OV 113
Schein JR 849
Schiff M 1181
Schiffman R 425
Schilz R 2007
Schimmer RC 391
Schnitzer TJ 151
Schoenknecht P 723
Schroeder J 723
Schulman KA 1527
Schwalen S 1423
Sebba AI 325 (E)
Secnik K 195, 1617
Segreti J 1923
Seidman L 1895
Selai CE 733
Semmons I 1819
Shabsigh R 1701
Shafran I 1165
Shah AK 595
Shah M 1651
Shah SR 1611
Shenolikar RA 323 (E)
Shepherd J 665
Shi J 1641
Shi L 555
Shikiar R 849
Shimizu K 503
Shingo S 141
Shinn AH 207
Shivaprakash M 2037
Shockey G 1241
Shoji N 503
Shortridge V 61
Shostak NA 113
Sides GD 1701
Silber S 619
Silva JM 1307
Silver G 723
Simonelli C 1069
Sittl R 1147
Sivakumar K 1961
Skrepnek GH 261
Sloan VS 151, 517
Smith DB 1181
Smith JW 207
Smith TJ 207
Song J 1241
Sörensen J 1819
Sougioultzis S 1337
Souza R 907
Spierings ELH S8 (Suppl 3)
Spiesser J 19
Spiller J 61, 245
Srivastava AK 1015
Staels B S13 (Suppl 1)
Stalenhoef AFH 1469
Stalla G 619
Stanford BL 1611
Stanford EJ 509
STAR (Singulair as Complementary Therapy to Fixed Association in Real life) Study Group 863
Stark WJ 93
Staskin DR 835
Statkevich P 1171
Staudinger H 1281
Stephens J 47
Stock JL 1955
Stockdale W 535
Stonecipher K 1057
Straus SMJM 1461
Stroes E S9 (Suppl 6)
Strow LJ 2029
Strutz F 1433
Study Group for the Validation of the DIB-R into Spanish 1251
Sturkenboom MCJM 839, 1461
Su M-Y 1595
Sung I 761
Suter P 761
Suyama H 503
Suzuki H 503
Swanson L 1069
Swensen AR 195
Swift JA 2051
Szerman N 1251
Szneke P 761

Tack CJ 1469
Tak Piech C 1677
Tan KM 173
Tang R 447
Tarride J-E 2017
Tepedino M 425
ter Avest E 1469
Theiler R 1727
Thiebaud D 1955
Thumann G 1569
Thurston H 517
Tohen M 555
Tossios P 1161
Tosti A 1829
Touchon J 1317
Toumi I 631
Tozzi CA 971
Trequattrini A 1809
Triantaffillidis JK 603
Trimarchi G 777
Trimble MR 733
Trope G 489
Truong D 467
Truyen L 1547
Tsianos E 603
Tung S-Y 1595
Tunis SL 555
Turner FD 683
Turunen H 1005
Tuttle E 1693

Upgrade Study Group 1809

Valdes J 61
Valentine WJ 19, 1617, 2063
Vallow SM 849
van Adelsberg J 971
van Baardewijk M 1271
van der Lei J 839
van der Sloot JAP 1865
Van Gaal L 665
Van Ganse E 1389
van Herpen G 1461
van Wijk MAM 839, 1461
van Wyk JT 839, 1461
Vanderplas AM 1583
van't Wout JW 1535
Vargha P 1943
Vellas B 1423
Vergès B S29 (Suppl 1)
Verhaeghe T 1547
Vetrugno M 1837
Vicente C 489, 2007
Viera MS 1829
Vieta E 923
Vigneri S 495
Virchow JC S19 (Suppl 4)
Vis PMJ 1271
Vliet EL 1015
Voelter-Mahlknecht 1041
Vogelson CT 683
von Eckardstein A S1 (Suppl 6)
Vorsanger G 849

Wade AG 631
Waeber B S13 (Suppl 5)
Wager E 317, 704 (L)
Wagner CL 1741
Walker JH 489, 2007
Walker M 1885
Walt J 1875
Walt JG 1837
Wan GJ 1485
Wang WC 1701
Wang Y-Y 447
Wasnich RD 391, 545
Watanabe Y 363
Waterhouse B 2029
Watson DJ 715
Watts NB 391
Wedel M 827
Weeks RL 877
Wehren L 185
Wehren LE 545
Wei LX 971
Wein A 835
Weiss TW 1069
Weissman P 2029
Wells DT 683
Wesnes K 1423
Wexner S 447
Weyne J 1377
Wheeler WJ 611
Whitcup SM 425
Wickstrøm J 1875
Wierzbicki AS 231, 299, 333, 959, 1201, 1717
Willey VJ 291
Williams C 1773
Williams D 1527
Williams P 413
Wittchen H-U 619
Wittrup-Jensen K 1477
Wong H-I 467
Wong J-M 1595
Wong M 1955
Wooddell MJ 2029
Wu EQ 1693
Wygant G 215
Wysocki S 509

Xie L 1027

Yaksic M 907
Yee RW 425
Yeon BK 1369
Yin D 1389
Yu C 715
Yuen C 1505

Zala C 1683
Zeiher AM 619
Zerbini C 2037
Zhao Q 483, 1547
Zhao Z 555
Zhu B 555
Zolmitriptan Study 014 Study Group 381
Zwinderman AH 1865

Keyword Index

Abnormalities 693
Absenteeism 535
Abstracts, structured 467
Acceptability 37
Access 339
Accreditation 307
ACE inhibitors 913, 1107
Acetaminophen 1217
Acetylcholinesterase 1631
Acetylcholinesterase inhibitors 1547
Acquired immunodeficiency syndrome 1717
Acute bacterial exacerbation 245
Acute bacterial sinusitis 61
Acute coronary syndromes 439, 1209
Acute renal failure 1161
Adherence 1281
Adipocytokines 457
Adjunctive 733
Adjuvant therapies 1985
Adverse effects 715
Adverse events 1261, 1441, 1569
Age-related macular degeneration 705
AIDS 1717
Alcoholic hepatitis 1337
Alendronate 185, 1895
Allergic conjunctivitis 683
Allergic rhinitis 611, 683, 971, 1099
Allergic rhinoconjunctivitis 683
Almotriptan 1603
Alpha 1-antitrypsin 877
Alpha 1-proteinase inhibitors 877
Aluminium salts 1949
Alzheimer's disease 483, 723, 871, 1317, 1423, 1547, 1631, 1809
Ambulatory blood pressure monitoring 113
Amikacin 645
Amlodipine 951
Amoxicillin/clavulanate 61
Anaemia 1347, 1527, 1677
Analgesia 141, 1819
Analgesic efficacy 1569
Analgesics 141, 517
Anastrozole 1985
Androgenetic alopecia 1829
Androgens 1227
Angina, unstable 1977
Angiotensin receptor blockers 1107
Antibiotics 1165
Antibiotics, ophthalmic 93
Anticoagulants 1085
Anticoagulation 215, 1905
Antidepressants 345, 1651, 1659
Antidepressant efficacy 1369
Antiemetics 885
Antiepileptic drugs 693, 733, 1065
Antihistamines 1099, 1377, 1495
Anti-inflammatories 61
Antimuscarinic therapies 835
Antipsychotics 1, 1809
Antivirals 761, 1577
Anxiety 941, 1651
Aphthous ulcers 1711
Aprepitant 595
Aquacel 81, 281
Aralast 877
Aromatase inhibitors 1985
Arrhythmias 95
Arsenic trioxide 403
Arterial stiffness S7 (Suppl 5)
Artificial tears 255
Asian 1201
Aspirin 101, 1217
Asthma 1075, S33 (Suppl 4)
Asthma control 863, S5 (Suppl 4)
Asthma management S1 (Suppl 4), S5 (Suppl 4), S11 (Suppl 4), S19 (Suppl 4), S27 (Suppl 4), S39 (Suppl 4)
Asthma severity 1519
Asymptomatic patients 1091
Atazanavir 1683
Atherogenesis S1 (Suppl 6)
Atherosclerosis S1 (Suppl 1), S13 (Suppl 1), 299, 1717, 1927
Atherosclerosis prevention S9 (Suppl 6)
Atopy 971
Atorvastatin 357, 777, 1307
Atrial fibrillation 215, 1085, 1583, 1693
Attention 1423
Attention deficit-hyperactivity disorder 195
Australia 1617
Azelastine nasal spray 611
Azithromycin 261

Back pain 1027, 1485, 1819
Bacterial conjunctivitis 425
Behavioural and psychiatric symptoms in dementia 1
Benzodiazepines 223, 941, 1809
Bimatoprost 1829, 1875
Bioequivalence 1961
Bioequivalents 769
Biphasic insulin aspart 2063
Bipolar disorder 555, 923
Bisphosphonates 391, 475, 805, 1453
Bleeding 439, 1085
Blepharospasms 433
β-Blockers 1191
Blood glucose 989
Blood glucose self-monitoring 173
Blood pressure 1755
Blood transfusions 447, 1677
BMI 1755
Body mass index 1755
Bone markers 1015
Bone microarchitecture 1049
Bone mineral density 391, 545, 579
Bone quality 1049
Bone remodelling 1015
Bone strength 1049
Bone turnover 1015, 1049
Bone turnover, biochemical markers 545
Borderline personality disorder 1251
Bosentan 907
Botulinum toxin type A 433
Breast cancer 805
Breastfeeding 693
Brinzolamide 503
Bronchitis, acute 1641
Budesonide 827, 1075
Buprenorphine 1147
Burden of illness 495
Burns 1235
Butyrylcholinesterase 207, 1631

Calcium channel blockers 951
Canada 1617, 2017
Cancer 271, 885
Candesartan cilexetil 935
Candidiasis, vulvovaginal 127
Carbamazepine 1065, 1363
Carboxymethylcellulose dressings 81, 281
Cardiac f-channel inhibitors 1115
Cardiac surgery 1161
Cardiomyocyte regeneration 795
Cardiopulmonary bypass 1161
Cardiovascular S41 (Suppl 1)
Cardiovascular disease 619, 665, 913, 1091, 1191, 1307, 1865, S1 (Suppl 1), S13 (Suppl 1), S21 (Suppl 1), 1461
Cardiovascular events S3 (Suppl 6)
Cardiovascular risks 135, 1201, 1433, 1927 1935
Carvedilol 1107, 1191
Cataract inflammation 1291
Cataract surgery 93
Cataract treatment strategy 1131
Celecoxib 47, 517
Cerebrovascular accidents 19, 1583
Cerebrovascular disorders 1461
Cervical dystonia 433
Channel blockers 1115
Chemotherapy 403, 1677, 1763
Children S27 (Suppl 4)
Cholesterol 231, 457, 1403, 1755
Cholesterol absorption inhibitors 571
Cholesterol-lowering drugs 1171
Cholinesterase inhibition 1631
Cholinesterase inhibitors 1, 871, 1317
Chorionic gonadotrophin 1969
Choroidal neovascularization 705
Chronic bronchitis 245
Chronic conditions 1801
Chronic hepatitis B 1845
Chronic kidney disease 981
Chronic low back pain 849
Chronic obstructive pulmonary disease 587, S19 (Suppl 4), S33 (Suppl 4), S39 (Suppl 4)
Chronic pain 1147, 1555, 1819
Chronic pelvic pain 509
CIKRON-H 1711
Cilostazol 817
Ciprofloxacin 1241
Claims database research 261
Clarithromycin 61, 245, 261
Clinical Global Impression-Severity 1659
Clinical guidelines 375
Clinical response 1181
Clinical trials 611, 715, 1527
Clinical vertebral fractures 1955
Clomiphene citrate 1035
Clopidogrel 101
Co-administration 571
Cohort studies 1461
Colesevelam HCl 1403
Colorectal cancer 447
Combination formulations 769
Combination therapies S1 (Suppl 6), 959
Communication 1297
Community-acquired infection 1641
Community-acquired pneumonia 261
Comparisons 1271
Compliance 935, 1453, 1651, 1943, S33 (Suppl 4)
Complications 1617
Congenital malformations 1075
Conservative management 1669
Consultation follow-up S11 (Suppl 4)
Consultations 339, 1595
Controlled clinical trials 971, 2037
Convenience 1895, S13 (Suppl 3)
Conventional tablets S13 (Suppl 3)
Corneal thickness 489
Coronary events 357
Coronary heart disease S7 (Suppl 5), 95, 299, 619, 959, 1201, 1307, 1389
Coronary heart disease risks 1755
Cost-effectiveness 101, 631, 1005, 1271, 1505, 1535, 1677, 2063
Cost-effectiveness analysis 913

Cost-utility analysis 1505, 2051
Costs 19, 81, 195, 271, 281, 291, 447, 805, 817, 913, 1617, 1829, 1885, 2063
Costs and cost analysis 2017
Costs of illness 19, 2017
COX-2 inhibitors 715, 1217
COX-3 1217
Cravings 749
C-reactive proteins S5 (Suppl 1), 207
Creatinine 1793
Crohn's disease 1165, 1741
Cross-study comparisons 835
Cryptosporidium parvum 999
Cultural adaptation 1251
Cyclo-oxygenase 151
Cyclo-oxygenase inhibitors 141
Cyclooxygenase-2 inhibitors 517
Cyclosporine ophthalmic emulsion 1057
CYP3A 363, 1641
Cystoid macular edema 1131, 1291

Daily activities S18 (Suppl 3)
Daptomycin 1923
Darbepoetin alfa 1347, 1677
Decompensated heart failure 1857
Delphi technique 311
Dementia 1, 1423
Dental pain 151
Depression 631, 1651
Desloratadine 1099
Devices S33 (Suppl 4)
Diabetes 619, 741, 1107, 1191, 1477, 1617, 1885, 1915, 1935
Diabetes complications 989
Diabetes mellitus S5 (Suppl 1), 163, 357, 989
Diabetes mellitus, type 2 173
Diabetes S13 (Suppl 1), S23 (Suppl 5), S41 (Suppl 1)
Diabetic dyslipidaemia S1 (Suppl 1), S29 (Suppl 1)
Diagnosis 1337
Diagnostic interview for borderlines (revised) 1251
Diagnostic tests 1347
Dialysis 1777
Diclofenac 2037
Dihydropyridines 951
Direct service costs 2017
Disease management 1935
Disease progression 981
Disease stability 489
Diuretics 37
Divalproex 555
DNA banking 1773
Docetaxel 1611
Donepezil 723, 871, 1317, 1809
Dosing 1363
Double-blind randomised controlled trials 1317
Doxorubicin 363
Drug combinations S13 (Suppl 5), S17 (Suppl 5)
Drug delivery S1 (Suppl 4)
Drug delivery devices S19 (Suppl 4)
Drug interactions 595, 1171, 1641
Drug safety 565
Dry eye syndrome 255, 1057
Dry power inhalers 827
Dry skin 1735
Dual action 345
Duloxetine 345, 1271, 1669
Duration of action 935
Dyslipidaemia S1 (Suppl 6), S9 (Suppl 6), S21 (Suppl 1), 665, 1927

Early breast cancer 1985
Early treatment S3 (Suppl 3)
Economics 195, 271, 291, 447, 2007
Economic assessments 261
Economic burdens 1693
Economic costs 375, 1915
Economic models 47
Effectiveness S3 (Suppl 3)
Efficacy 37, 127, 333, 345, 381, 571, 603, 1603
Eflornithine 1227
Elderly 1, 37, 339
Embryogenic carcinoma cells 795
Emesis 885, 1763
Emphysema 877
EMPIRE 2029
Enalapril S17 (Suppl 5), S23 (Suppl 5)
End-stage renal disease 657
Endothelial function 1469
Endothelins 327
Endpoint determination 1527
Entecavir 1845
Epidemiology 1069
Epilepsy 733, 1065
Epoetin alfa 1347, 1677
Epoprostenol 2007
EQ-5D 733, 1209
Erectile dysfunction 1065, 1701
Erythromycin 261
Erythropoiesis-stimulating protein 981
Erythropoietin 1527
Escitalopram, cost of 631
Essential hypertension 951
Ethics 307
Etoposide 363
Etoricoxib 141, 715, 2037
Europe 565
Evening dosing 1281
Exemestane 1985
Extended release 245, 483, 1241, 941, 1363, 1547
Ezetimibe 333, 959, 1123, 1171

Factor analysis 749
Faecal impaction 1595
Familial combined hyperlipidaemia 333, 1469
Familial hypercholesterolaemia 333
Family burdens 195
Fast-acting S3 (Suppl 3)
Fenofibrate 1403, 1997
Fentanyl 271, 1961
Ferritin 527
Fever 645
Fexofenadine 769, 1099, 1495
Filled-by-mass 121
Fine particle dose 827
Fixed association 863
Flow mediated dilation 1469
Fluoroquinolones 93, 425
Fluoxetine 1369
Fluvastatins 231, 1171
Follicle-stimulating hormone 899
Follicle-stimulating hormone, recombinant human 121
Food effects 1547
Forearm blood flow 1469
Formulation 369
Fractures 391, 475, 545, 579, 1355
France 1617
Freeze dried 121
Friction cost method 2017
Functional capacity 907

Galantamine 483, 871, 1423, 1547, 1809
Gastro-oesophageal reflux disease 27, 535, 603, 1505
Gastrointestinal 715
Gatifloxacin 93, 425
Gauzes 81, 281
Genetic polymorphisms 1041
Genetic research 1773
Genetic testing 1041
Genital herpes 1577
Germany 81, 1617
Ghost authorship 311, 317
Ghost writing 307, 311, 317
Giardia lamblia 999
Glargine 291
Glaucoma 503, 1829, 1875
Glitazones S1 (Suppl 1), S13 (Suppl 1)
Glomerular filtration rate 1201
Glucose 1157
Glucose metabolism disorders 113
Glucose tolerance test 989
Glycaemic control 1885, 2029
Gonadotrophin 899
Graft rejections 1793
Granisetron 363
Guidelines S1 (Suppl 6), S3 (Suppl 6), 317, 959

Haematological malignancies 403
Haemoglobin 1347
Haemoglobin A, glycosylated 173
Hair loss 1829
HBV DNA polymerase inhibitors 1845
HDL 1755
HDL-cholesterol 1927
Headaches 1297
Headache pains S18 (Suppl 3)
Headache responses S8 (Suppl 3)
Health care 195
Health care costs 2017
Health care workers 741
Health expenditures 1977
Health maintenance organisation 1977
Health Outcomes Survey 1801
Health-related quality of life 495, 849, 1209
Health status 733, 1209, 1801
Heart valve prostheses 1085
Heart-rate reducing agent 1115
Heartburn 495
Hemifacial spasm 433
Hepatitis C virus 527
High-density lipoproteins 1755, 1997, (Suppl 6)
High-density lipoprotein cholesterol 299, 457, 1307, 1865, S1 (Suppl 6), S3 (Suppl 6)
Highly active antiretroviral therapy 1683
Highly purified urine-derived hCG 1969
Highly purified urine-derived FSH 899
Hip fractures 1355, 1891
Hirsutism 1227
Histamine$_2$ receptor antagonists 11
Histology 1741
Histomorphometry 185
HIV 231, 1683, 1717
Hormonal supplementation 1035
Hormone replacement therapy 2051
Hospitals 741
HP-Guar gellable lubricant eye drops 255
5-HT 885
HIV 231, 1683, 1717
Human menopausal gonadotrophin 899
Hyaluronan 1261
Hyaluronic acid 1235, 1727
Hydrofibers 281
Hydroxymethylglutaryl-CoA reductase inhibitors 1091, 1389
Hylan G-F 20 1261
Hypercholesterolaemia 571, 839, 1123, 1389
Hyperlipidemia 1091
Hyperphosphatemia 657
Hypersensitivity reactions 1611
Hypertension 37, 619, 839, 935, 1433, 2007, S1 (Suppl 5), S7 (Suppl 5), S13 (Suppl 5), S17 (Suppl 5), S23 (Suppl 5)
Hypnotics 1785
Hypoglycaemia 291, 1477

Ibandronate 391, 1895
Idiopathic hyperhidrosis 1949
I_f current 1115
Imipenem 645, 785
Immunohistochemistry 1741
Inadequacy 1069

Incontinence 71, 835
Indapamide S13 (Suppl 5), S17 (Suppl 5), S23 (Suppl 5)
Indapamide SR 37
Infections 785
Inflammation 1741, S5 (Suppl 1)
Inflammatory bowel disease 1165, 1741
Infliximab 1181, 1741
Influenza 761
Information S11 (Suppl 4)
Inhalation devices S5 (Suppl 4), S1 (Suppl 4), S27 (Suppl 4)
Inhalation therapy S33 (Suppl 4), S39 (Suppl 4)
Inhaled corticosteroids 1519
Inhaler choice S19 (Suppl 4)
Inhaler devices S39 (Suppl 4)
Inhibitors 587
Injections 1915
Insomnia 223
Insulin 291, 457, 741
Insulin glargine 2063
Insulin resistance 527, 1157, S21 (Suppl 1)
Intermittent claudication 817
International normalized ratio 215
Interstitial cystitis 509
Intra-articular 1727
Intraocular pressure 489, 503, 1829, 1875, 1943
Invasive aspergillosis 1535
Irbesartan 1433
Irinotecan 363
Isolated systolic hypertension 37
Italy 495, 1617, 1829
Ivabradine 1115

Japanese 1495

Keratoconjunctivitis sicca 1057
Ketolides 1641
Knees 517, 1261
Knee osteoarthritis 1727
Korean patients 1369

Lamiracoxib 517
Lanthanum carbonate 657
Latanoprost 503, 1875
Latino patients 1935
Lauromacrogols 1735
Laxatives 1595
LDL-cholesterol 333
LDL-C/HDL-C ratios 1865
Left ventricular hypertrophy S17 (Suppl 5)
Leg ulcers 81
Letrozole 1985
Leukaemia 403
Levocetirizine 1099
Levodopa/carbidopa/entacapone 1005
Levofloxacin 261
Lipids 163, 231, 457, 1123, 1403, 1717
Lipid disorders 619
Lipid-lowering S9 (Suppl 6)
Lipid-lowering therapy 299
Lipodystrophy 1717
Lipoproteins 113, 207
Lipoprotein(a) S3 (Suppl 6)
Liquids 121
Lisinopril 113
Locally advanced prostate cancer 1329
Long-term studies 657
Long-term treatments 37, 1659
Lopinavir 1683
Loratadine 1495
Low back pain 2037
Low-density lipoproteins S17 (Suppl 6), 777
Low-density lipoprotein cholesterol 959, 1307, S1 (Suppl 6), S9 (Suppl 6)
Lumiracoxib 151
Lung deposition 827
Lung inflammation 587
Luteinizing hormone releasing hormone analogues 1329

Macrogol 1595
Macrovascular disease S5 (Suppl 1)
Maintenance dosages 1181
Major depression 1271
Major depressive disorders 345, 1139
Managed care 1801
Management 1337
Mania 555, 923
Markov model 101, 1005, 1505
Mast cell stabilizer 1377
Matrix metalloproteinases 327, 587
Mechanical treatments 1227
Mechanism of action 95
Medical costs 1693
Medical writing 317
Medicare 1801
Memantine 723
Menopause 2051
Meropenem 785
Meta-analysis 785, 1123
Metabolic parameters 1997
Metabolic syndrome 163, 665, 1107, 1157, 1997, S1 (Suppl 1), S21 (Suppl 1)
Metabolic syndrome X 113
Metamizol 1569
Metformin 2029
Methotrexate 1181
Metopimazine 1763
Miconazole 127
Micro-computed tomography 185
Microalbuminuria 1433
Microarchitecture 185
Microvascular changes S1 (Suppl 5)
Migraines 375, 381, 413, 1297, 1603
Migraine-related disabilities S18 (Suppl 3)
Milnacipran 1369
Mixed dementia 871
Mixed hyperlidpidemia 1403
Mixed rhinitis 611
Modelling 2063
Modelling and simulation 483
Models 1363, 1617
Moderate depression 1659
Mometasone furoate 1281
Montelukast 863, 971
Montgomery-Åsberg Depression Rating Scale 1659
Morphine 271
Mortality 439, 1905
Mouth mucosa 1711
Moxifloxacin 93
Multinational 1785
Muscle relaxants 1485
Musculoskeletal pains 1485
Myocardial infarction 439, 1977

Naftidrofuryl 817
Nasal 683
Nateglinide 989
Nausea and vomiting 595
Neck pain 1485
Needlestick injuries 741, 1915
Nesiritide 1857
Neurokinins 885
Neurologists 413
Neuropsychiatric disturbances 1631
Neutropenia 645
NHS 1005
Nicotine 749
Nicotinic acid 299, 665, S17 (Suppl 6)
Nilvadipine 951
Nitazoxanide 999
Nocturia 1413
Non-allergic rhinitis 611
Non-compliance S5 (Suppl 4)
Non-interventional studies 1147
Non-malignancies 1555
Non-response 1603
Non-steroidal anti-androgen therapy 1329
Non-steroidal anti-inflammatory drugs 47, 715, 1131, 1217, 1485
Nootropics 723
North American 1069
Novolizer S39 (Suppl 4)
NT-proBNP 907
Nurses 741, 1915
Nyperglycaemia 989

Obesity 163, 1997
Observational stdies 291, 723, 1147
Ocular allergies 683, 1377
Olanzapine 555
Olopatadine 683, 1377
Omega-3 fatty acids 95
Once daily 1281
Ondansetron 1763
Opioids 141, 1147, 1819
Opioid analgesics 1555
Opioid therapy 849
Oral S3 (Suppl 3)
Orally disintegrating tablets 381, S13 (Suppl 3)
Orlistat 1885, 1997
Oseltamivir 761
Osteoarthritis 151, 517, 1261
Osteomalacia 579
Osteomyelitis 1923
Osteopenia 1015
Osteoporosis 135, 185, 391, 475, 545, 579, 1015, 1049, 1355, 1891, 1955
Osteoporosis treatment 1027
Osteoporotic 1069
Outcomes S41 (Suppl 1)
Overactive bladder 71, 835, 1413
Oxcarbazepine 693, 1065, 1363
Oxidation 777
Oxidative stress 1161

P19CL6 795
Pacemakers 1115
Paclitaxel 1611
Pain 517, 1261, 1297
Palliative care 271
Palonosetron 595
Pamidronate 805
Paracetamol 1569
Parathyroid hormone 1027, 1891
Parkinson's disease 1005
Paroxetine 1139
Pathophysiology 1337
Patient choices 1329, S5 (Suppl 4)
Patient consultations S11 (Suppl 4)
Patient management 839
Patient-physician communication S11 (Suppl 4)
Pediatric asthma 971
Pentosan polysulfate sodium 509
Pentoxifylline 817
Peptic ulcer disease 535
Perindopril S13 (Suppl 5), S17 (Suppl 5), S23 (Suppl 5)
Peroxisome proliferator-activated receptor gamma S13 (Suppl 1)
Persistence 1453
Persistent diarrhea 999
Personalised medicine 1041
pH monitoring, gastric, esophageal 27
Pharmaceutical industry 1041, 2007
Pharmacodynamics 1171
Pharmacogenomics 1041
Pharmacokinetics 121, 369, 483, 595, 769, 1171, 1547, 1641
Pharmacological management 1669
Pharmacotherapy 71
Pharmacovigilance 565
Physician relationships 1297
Pioglitazone 163, S41 (Suppl 1)
Piperacillin/tazobactam 645
Placebo effect 835
Placebos S8 (Suppl 3)
Plaque regression S17 (Suppl 6)
Platelets S5 (Suppl 1)
Pleiotropic effects 231
PML-RAR gene 403
Pneumonia 761, 1641

Polycystic ovary syndrome 1227
Polyethylene glycol 1595
Polymer hydroxypropyl guar 255
Polyphenols 1711
Polysomnography 223
PON1 777
Population studies 1905
Postmarketing studies 565
Postmarketing surveillance studies 565, 723, 603
Postmenopausal 1027, 1955
Postmenopausal osteoporosis 1453
Postmenopausal therapies 135
Postoperative analgesia 1569
Postprandial glucose control 989
Predictors 475
Prednisolone acetate 1291
Preferences 1895
Pregnancy 693, 1075
Pregnancy rates 1035
Prevalence 619, 1157, 1785, 1927
Prevention 1107
Prevention and control 1389
Primary care 339, 839
Primary care physicians 413
PROactive S41 (Suppl 1)
Probabilistic analysis 1005
Probabilistic sensitivity analysis 47
Productivity 535, 1477
Professional ethics 311, 317
Professional writers 307
Progesterone 1035
Prolastin 877
Prospective Cardiovascular Münster (PROCAM) S3 (Suppl 6)
Prostaglandins 503, 1217
Protease inhibitors 1683
Proton pump inhibitors 11, 603, 1505
Proton pump inhibitor therapy 27
Pruritus 1735
Pseudoephedrine 769
Psychological 1829
Psychology 1297
Psychometrics 749, 1209
Psychosis 1
Psychosocial well-being 1829
Public attitudes 1773
Publications 311, 317
Pulmonary 2007
Pulmonary arterial hypertension 327
Pulmonary hypertension 907
Pulse pressure 1433, S7 (Suppl 5)

Quality 467
Quality of life 733, 907, 1085, 1281, 1413, 1477, 1555, 1777
Quality-adjusted life years 101, 2051
Quetiapine 923

Rabeprazole 603
Raloxifene 135, 1441, 1955
Ramipril 913
Randomised controlled trials 1139
Randomised studies 1763
Rapid response S8 (Suppl 3)
Recombinant human chorionic gonadotrophin 1969
Regenerative medicine 795
Reliability 749, S3 (Suppl 3)
Remission 1139, 1659
Renal disease 1201
Renal failure 1777
Renal function 231, 357, 981, 1857
Renal transplants 1777, 1793
Research, medical journals 467
Research design 467
Resource uses 271, 447, 1477
Retinal surgery 1569
Rheumatoid arthritis 151
Rhinitis 1075
Rhizophora mangle 1711
Rifaximin 1165
Rilmenidine 113
Riotonavir 1683
Risk factors 207, 619, 1091, 1577, S3 (Suppl 6)
Risk of recurrence 1985
Rivastigmine 871, 1317, 1631, 1809
Rizatriptan S13 (Suppl 3)
Rofecoxib 47
Rosiglitazone 2029
Rosuvastatin 1307, 1469, 1865
Routine 1347

Safety 127, 369, 603, 1369, 1441
Safety needles 741
Satisfaction 1701
Schizophrenia 2017
Screening 839
Seasonal allergic rhinitis 769
Seasonality 1891
Secondary prevention 95
Secondary prevention, occlusive vascular event 101
Selective estrogen receptor modulators 135
Selective serotonin reuptake inhibitors 1651
Selectivity 587
Self-care 173
Self-esteem 1829
Semi-structured interviews 1251
Septic arthritis 1923
Serum paraoxonase 777
Sexual behaviours 1701
SF-36 1801
SF-36 survey 1085
Sharps injury 741
Sibutramine 457
Silver sulfadiazine 1235
Sinoatrial node 1115
Sinovial 1727
Sinusitis 1641
Sleep architecture 223
Sleep disorders 1785
Sleep efficiency 223
Sleep maintenance 223
Smoking cessation 749
Social medicine 1041
Solifenacin succinate 71
Soya oil 1735
Spain 1617
Spanish 1251
Spasms 1485
ST-segment elevation MI 439
Stability 1905
Statins 207, 231, 571, 959, 1171, 1389, 1461, S1 (Suppl 6), S3 (Suppl 6), S9 (Suppl 6), S17 (Suppl 6)
Statin therapies 1123
Steroid tapering 1281
Stress urinary incontinence 1669
Stress-related mucosal disease 11
Strokes S7 (Suppl 5), 19, 357
Sumatriptan 1603, S13 (Suppl 3)
Supportive care 885
Surgery, oral 141
Surgical management 1669
Surgical site infections 447
Surgical wounds 281
Surrogate markers 907
Surveys 1785
Survival 1793
Sustained release 941
Sustained response S8 (Suppl 3)
Switching 375, 1809
Syndrome X 163
Systematic reviews 785
Systemic sclerosis 327

Tadalafil 1701
Tapering 1181
Taxanes 1611
TBARS 777
Tear supplements 255
Telephones 339
Telithromycin 1641
Temazepam 223
Teriparatide 1027
Test doses 1611
Therapeutic equivalency 121
Thermophobic foam 1949
Thiazolidinediones 163, S1 (Suppl 1), S13 (Suppl 1), S21 (Suppl 1), S29 (Suppl 1), S41 (Suppl 1)
Thromboembolic events 215
Thromboembolism 1583
Thrombosis S5 (Suppl 1)
Time to symptom relief 1241
Timolol 369, 1875
TNF-alpha inhibition 527, 1337
Tolerability 345, 381, 1659, S18 (Suppl 3)
Topical treatments 1227
Trabeculectomy 1829
Training S27 (Suppl 4)
Transdermal 1961
Transfusions 1347
Transient ischemic attacks 19
Transmission 1577
Transparency 307
Transplantation 795
Travoprost 1875, 1943
Trazodone 1139
Treatments 839, 885, 1535, 1785
Treatment costs 555
Treatment outcomes 1461, 1583
Treatment recommendations 1519
Treprostinil 2007
Trials 1441
Triamcinolone acetonide 705
Triglycerides 1307, 1403, 1997, S29 (Suppl 1)
TRIPSTAR 413
Triptans 375, 413, 1603, S3 (Suppl 3)
Tumour necrosis factor alpha 527, 1337
Type 2 diabetes 457, 665, 1433, 2029, S21 (Suppl 1), S29 (Suppl 1)
Type 2 diabetes management S1 (Suppl 1)

UK 2063
Uncomplicated urinary tract infection 1241
Undertreatment 839
United Kingdom 101, 281, 565, 631, 805, 817
United States of America 81, 281
Unstable angina 439
Uric acid 457
Urinary incontinence 1413, 1669
Urinary symptoms 1413
Urine-derived FSH 899
Utilization evaluation 1857

Vaginal progesterone gel 1035
Valacyclovir 1577
Validation 1251
Validity 749
Variability 827, 1519
Vascular complications 357
Vascular risk 1157
Venlafaxine-XR 1271
Verteporfin therapy 705
Veterans Health Administration 47
Viscosupplementation 1727
Visual fields 489
Vitamin D 579, 1069
Vitamin D inadequacy 1355, 1891

Waist circumference 1157
Warfarin 215, 1583, 1905
Weight changes 1885
Weight loss 457
Well-being 1297
Wheal and flare 1495
Withdrawal scales 749
Work loss 195, 535
Workplace costs 1693
Wound healing 1235

Zemaira 877
Zoledronic acid 805
Zolmitriptan 381, S13 (Suppl 3)
Zolmitriptan orally disintegrating tablets S8 (Suppl 3), S18 (Suppl 3)